RSS Feeds
Hospice Benefits and Phase I Cancer Trials
- Ira Byock, MD; and
- Steven H. Miles, MD
- From The Practical Ethics Center, University of Montana; Missoula, MT 59812; and Center for Bioethics, University of Minnesota; Minneapolis, MN 55455.
The Editors welcome submissions for possible publication in the Letters section. Authors of letters should:
•Include no more than 300 words of text, three authors, and five references
•Type with double-spacing
•Send three copies of the letter, an authors' form signed by all authors, and a cover letter describing any conflicts of interest related to the contents of the letter.
Letters commenting on an Annals article will be considered if they are received within 6 weeks of the time the article was published. Only some of the letters received can be published. Published letters are edited and may be shortened; tables and figures are included only selectively. Authors will be notified that the letter has been received. If the letter is selected for publication, the author will be notified about 3 weeks before the publication date. Unpublished letters cannot be returned.
Annals welcomes electronically submitted letters.
IN RESPONSE:
We asserted that people who qualify for hospice care under Medicare must not be rendered ineligible for hospice services if they choose to enter a phase I trial. We do not share Dr. Avery's view that people who enroll in hospice should not be allowed to participate in phase I trials. Hospice is a service delivery model for providing palliative care. Neither research nor patient care is served by denying patients with incurable cancer the opportunity to contribute to determining safe doses for therapies that may help others. Many terminally ill patients value a sense of contributing to others (1). People with advanced, incurable cancer may well benefit from receiving hospice services as they participate in clinical research. The Promoting Excellence in End-of-Life Care program sponsored 4 cancer programs of concurrent oncology care, including participation in phase I and phase II clinical trials, and palliative care. These projects were well received by patients, families, and clinicians (2).
We agree with Dr. Trump that hospice care should be available to eligible patients who enter phase II trials to test new treatment regimens against a placebo. Such patients are misled if they believe the experimental protocols represent effective treatments and are disserved if their willingness to participate in research precludes receiving funded hospice services. Institutional review boards must examine research protocols to ensure compliance with standards for providing palliative care. They must scrutinize the informed consent process to ensure that terminally ill persons are not denied the opportunity to receive services that may benefit them and their families.
Ira Byock, MD
The Practical Ethics Center, University of Montana
Missoula, MT 59812
Steven H. Miles, MD
Center for Bioethics, University of Minnesota
Minneapolis, MN 55455
The Editors welcome submissions for possible publication in the Letters section. Authors of letters should:
•Include no more than 300 words of text, three authors, and five references
•Type with double-spacing
•Send three copies of the letter, an authors' form signed by all authors, and a cover letter describing any conflicts of interest related to the contents of the letter.
Letters commenting on an Annals article will be considered if they are received within 6 weeks of the time the article was published. Only some of the letters received can be published. Published letters are edited and may be shortened; tables and figures are included only selectively. Authors will be notified that the letter has been received. If the letter is selected for publication, the author will be notified about 3 weeks before the publication date. Unpublished letters cannot be returned.
Annals welcomes electronically submitted letters.
- Copyright ©2004 by the American College of Physicians
